Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Bibliographic Details
Main Authors: Daniel Morales-Cano, Jose Luis Izquierdo-García, Bianca Barreira, Sergio Esquivel-Ruiz, Maria Callejo, Rachele Pandolfi, Palmira Villa-Valverde, Ignacio Rodríguez, Angel Cogolludo, Jesus Ruiz-Cabello, Francisco Perez-Vizcaino, Laura Moreno
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pharmacology
Subjects:
pulmonary hypertension
antiproliferative
metabolomics
combination therapy
right ventricle
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1228923/full

Similar Items

Similar Items